TOKYO -- Takeda Pharmaceutical aims to restore health to its balance sheet within five years after taking on hefty debt to finance the $58 billion-plus purchase of Ireland's Shire, Takeda's CEO told Nikkei on Nov. 6.
Interview
Takeda CEO vows to fix balance sheet within 5 years
Japanese drugmaker will consolidate US operations after Shire purchase, Weber says
Takeda aims to reduce its debt load by tapping synergies from the acquisition.
Read Next
Latest on Interview
